Systematic Review
Published on 06 Feb 2026
Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis
in Drugs Outcomes Research and Policies
- 206 views